The value of proteasome inhibition in cancer
- 1 August 2008
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 13 (15-16) , 716-722
Abstract
No abstract availableKeywords
Funding Information
- Grantová Agentura České Republiky
- Ministerstvo Školství, Mládeže a Tělovýchovy (GACR 303/08/P137)
This publication has 87 references indexed in Scilit:
- Docking of the Proteasomal ATPases' Carboxyl Termini in the 20S Proteasome's α Ring Opens the Gate for Substrate EntryMolecular Cell, 2007
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Aging and regulated protein degradation: who has the UPPer hand?Aging Cell, 2007
- Ubiquitin-Independent Degradation of Cell-Cycle Inhibitors by the REGγ ProteasomeMolecular Cell, 2007
- Phosphorylation of CBP by IKKα Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF-κBMolecular Cell, 2007
- CSN controls NF‐κB by deubiquitinylation of IκBαThe EMBO Journal, 2007
- Integrating cell-signalling pathways with NF-κB and IKK functionNature Reviews Molecular Cell Biology, 2007
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- Nuclear factor-κB in cancer development and progressionNature, 2006